6 results on '"Jiang, Chen"'
Search Results
2. Yi-shen-hua-shi granules modulate immune and inflammatory damage via the ALG3/PPARγ/NF-κB pathway in the treatment of immunoglobulin a nephropathy.
- Author
-
Xu, Rongjia, Zhang, Jiajia, Hu, Xingge, Xu, Penghao, Huang, Shiqi, Cui, Shiyan, Guo, Yuxin, Yang, Hongtao, Chen, Xiangmei, and Jiang, Chen
- Subjects
- *
INFLAMMATION prevention , *DRUG efficacy , *FLOW cytometry , *HERBAL medicine , *ANIMAL experimentation , *IMMUNE system , *CELLULAR signal transduction , *RATS , *DESCRIPTIVE statistics , *GLOMERULONEPHRITIS , *DATA analysis software , *BIOLOGICAL assay , *CHINESE medicine , *THERAPEUTICS - Abstract
Controversy persists regarding the treatment of immunoglobulin A nephropathy (IgAN), thereby highlighting the demand for safer more effective therapeutic drugs. Although supplementary treatment using Yi-Shen-Hua-Shi (YSHS) granules has distinct advantages with respect to improving renal function in IgAN, a lack of clarity regarding the underlying mechanisms limits their clinical application. In this study, we aimed to elucidate the therapeutic mechanisms underlying the efficacy of YSHS granules in the treatment of IgAN. A rat model of IgAN was established based on lipopolysaccharide, carbon tetrachloride, and bovine serum albumin induction. In order to evaluate the effects of YSHS granules, we performed a range of techniques, including immunofluorescence assays, hematoxylin and eosin staining, and flow cytometry, to assess inflammation, immunity, and other relevant factors. Direct data-independent acquisition–mass spectrometry (DIA-MS) analysis and parallel reaction monitoring (PRM) were used for functional characterization and quantitative validation of differentially expressed proteins (DEPs), and Western blot analysis is used to identify downstream proteins associated with DEPs. Compared with the model group, the levels of proteinuria, urine red blood cells, serum creatinine, blood urea nitrogen, low-density lipoprotein-cholesterol, triglycerides, and pathological kidney damage were reduced in the YSHS group. A high dose of YSHS granules was found to raise the levels of CD8 T cells and reduce the CD4/CD8 ratio in the peripheral serum. To examine the mechanisms underlying the therapeutic effects YSHS granules, we performed direct DIA-MS analysis to identify proteins that were differentially expressed among the model, YSHS, and control groups. A total of 29 proteins were identified as being commonly expressed in all three groups. Further KEGG and protein–protein interaction (PPI) network analysis revealed that YSHS granules can contribute to the regulation of N -glycosylation-associated proteins, such as ALG3 and STT3A, in rats with IgAN. Detected changes in the expression of ALG3 and STT3A were consistent with the PRM results. We also established that the administration of YSHS granules can contribute to regulation of the ALG3-associated PPAR-γ/NF-κB signaling pathway. Our findings in this study provide evidence to indicate the efficacy of YSHS granules in the treatment of IgAN, the putative underlying mechanisms of which involve the modulation of N-glycosylation, mediated via the PPAR-γ/NF-κB pathway. A detailed flow chart of the study design. The effects of YSHS granules on immune disorders, inflammatory injury, and metabolic disorders in IgAN rats were assessed using a rat model in which IgAN was induced by lipopolysaccharide (LPS), carbon tetrachloride (CCl4), and bovine serum albumin (BSA). To investigate the mechanisms underlying the therapeutic effects of YSHS granules, we performed direct data-independent acquisition mass spectrometry (DIA-MS) analysis. Further Kyoto Encyclopedia of Genes and Genomes and protein–protein interaction network analysis indicated that YSHS granules regulate N-glycosylation-associated proteins, including ALG3 and STT3A, in rats with IgAN. On the basis of Western blot analysis, we demonstrated that YSHS granules regulate the ALG3-associated PPAR-γ/NF-κB signaling pathway. [Display omitted] • YSHS granule improves IgAN renal function but mechanism unknown. • Proteomic data reveals 29 targets and N-glycosylation in YSHS against IgAN. • ALG3, a key protein,regulates immune and inflammation related proteins. • YSHS granule regulates ALG3/PPAR-γ/NF-κB in the treatment of IgAN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Stereotactic body radiation therapy for refractory ventricular tachycardia secondary to cardiac lipoma: A case report.
- Author
-
Zeng, Li‐Jun, Huang, Li‐Hong, Tan, Hong, Zhang, Hou‐Cai, Mei, Ju, Shi, Hai‐Feng, Jiang, Chen‐Yang, Tan, Chen, Zheng, Jian‐Wei, and Liu, Xing‐Peng
- Subjects
- *
MYOCARDIAL depressants , *CATHETER ablation , *HEART tumors , *PATIENT aftercare , *RADIATION doses , *RADIOSURGERY , *VENTRICULAR tachycardia , *DECISION making in clinical medicine , *TREATMENT effectiveness , *LIPOMA , *DISEASE complications , *THERAPEUTICS ,DISEASE relapse prevention - Abstract
We present the case of a 29‐year‐old man who developed ventricular tachycardia (VT) secondary to a cardiac lipoma located adjacent to the interventricular groove, which could not be fully resected. Antiarrhythmic drugs and endocardial and epicardial ablation failed to prevent VT recurrence. Finally, noninvasive stereotactic body radiation therapy (SBRT) targeting the lipoma was performed, with a total dose of 24 Gy delivered in three fractions. The number of VT episodes was reduced from 189/24 h before SBRT to 0 after the procedure. At 4‐month follow‐up, there were no signs of therapy‐related complications. Our experience suggests that SBRT could emerge as a viable treatment option for patients with cardiac tumors who develop refractory ventricular arrhythmias. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome.
- Author
-
Daimin Wei, Yuhua Shi, Jing Li, Ze Wang, Lin Zhang, Yun Sun, Hong Zhou, Yuping Xu, Chunxiang Wu, Ling Liu, Qiongfang Wu, Lili Zhuang, Yanzhi Du, Weiping Li, Heping Zhang, Legro, Richard S., Zi-Jiang Chen, Wei, Daimin, Shi, Yuhua, and Li, Jing
- Subjects
- *
ORAL contraceptives , *PROGESTATIONAL hormones , *POLYCYSTIC ovary syndrome treatment , *HUMAN in vitro fertilization , *EMBRYO transfer , *PREGNANCY complications , *THERAPEUTIC use of progestational hormones , *BIRTH rate , *COMPARATIVE studies , *FERTILIZATION in vitro , *RESEARCH methodology , *EVALUATION of medical care , *MEDICAL cooperation , *INDUCED ovulation , *PREGNANCY , *RESEARCH , *STATISTICAL sampling , *POLYCYSTIC ovary syndrome , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
Study Question: Do oral contraceptives (OCs) and progestins impact live birth rate of IVF when used for cycle scheduling in women with polycystic ovary syndrome (PCOS)?Summary Answer: OCs used for scheduling IVF cycle were associated with lowered rates of pregnancy and live birth after fresh embryo transfer, whereas progestins used for this purpose yield higher rates of pregnancy and live birth than OCs.What Is Known Already: Due to oligo-menorrhea in PCOS, OCs and progestin are extensively used to schedule the start of an IVF cycle in women with PCOS. Little is known about the effect of such pretreatments on outcomes, especially, the rate of live birth.Study Design, Size, Duration: This was a nested cohort study and secondary analysis of a multicenter randomized trial, which was designed to compare live birth rate after fresh embryo transfer vs frozen embryo transfer (FET) in women with PCOS (Frefro-PCOS). A total of 1508 women were enrolled from 14 centers between June 2013 and May 2014.Participants/materials, Setting, Methods: At the discretion of local investigators, subjects were instructed to wait for spontaneous menses (Control group, n = 323), or were prescribed progestins (P group, n = 283) or OCs (OCs group, n = 902) to induce menstruation prior to the start of ovarian stimulation. GnRH antagonist protocol was initiated at Day 2 or 3 of induced or spontaneous menses cycle. The rates of pregnancy, pregnancy loss and live birth after either fresh embryo transfer or FET were compared among these three groups.Main Results and the Role Of Chance: With fresh embryo transfer, women with OC-induced menses had lower rates of clinical pregnancy (48.8% vs 63.6%, relative rate (RR): 0.77, 95% CI: 0.66-0.89) and live birth (36.1% vs 48.1%, RR: 0.75, 95% CI: 0.61-0.92) than women with spontaneous menses. With freeze-all and deferred FET, women with OC-induced menses had a similar pregnancy rate but a higher pregnancy loss rate (27.7% vs 13.0%, RR: 2.13, 95% CI: 1.28-3.52) after FET than women with spontaneous menses. The live birth rate after FET in women with OC-induced menses, progestin-induced menses and spontaneous menses was 49.4%, 50.7% and 60.2%, respectively (P = 0.06). Progestin-induced menses was associated with similar rates of pregnancy, pregnancy loss and live birth after transfer of either fresh or frozen embryos compared with spontaneous menses. Multivariate logistic regression analysis showed that OCs used for menses induction was associated with lower rate of live birth.Limitations, Reasons For Caution: The methods for menses induction were not assigned randomly, thus selection bias was highly likely because of the study design and significant differences that were observed in the baseline characteristics of the women in the different groups. The mean BMI in this study population was relatively normal; the applicability of this result to obese PCOS women needs to be evaluated in further study.Wider Implications Of the Findings: Our results suggest that either waiting for a spontaneous menses or using progestin is a better option than using OCs to induce menses in women with PCOS prior to ovarian stimulation using GnRH antagonist protocol for IVF. Further randomized controlled studies are needed to confirm our findings.Study Funding/competing Interests: This study was funded by National Basic Research Program of China (973 Program) (2012CB944700), the State Key Program of National Natural Science Foundation of China (81430029), National Natural Science Foundation of China (81471428) and Thousand Talents Program (Drs Legro and Zhang H). Dr Legro reports receiving consulting fees from Euroscreen, Kindex, Bayer and Millendo Pharmaceuticals and research funding from Ferring. Others report no disclosures.Trial Registration Number: Frefro-PCOS was registered at Clinicaltrials.gov: NCT01841528. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
5. Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor.
- Author
-
Xue, Meiyan, Hu, Steven, Lu, Yifei, Zhang, Yu, Jiang, Xutao, An, Sai, Guo, Yubo, Zhou, Xue, Hou, Huimin, and Jiang, Chen
- Subjects
- *
DRUG development , *CHITOSAN , *NANOPARTICLES , *DRUG delivery systems , *PROTOTYPES , *CAPSIDS , *THERAPEUTICS - Abstract
Oral delivery of biopharmaceutics drug disposition classification system (BDDCS) Class II or IV drugs with poor aqueous solubility and poor enzymatic and/or metabolic stability is very challenging. Bay41-4109, a member of the heteroaryldihydropyrimidine (HAP) family, inhibits HBV replication by destabilizing capsid assembly. It pertains to class II of the BDDCS which has a practically insoluble solubility which is 38 μg/mL (LYSA) and the oral delivery resulted in low bioavailability. The purpose of the current research work was to develop and evaluate Bay41-4109 loaded chitosan nanoparticles to increase the solubility and bioavailability for treatment of HBV. The Bay41-4109 nanoparticles were prepared by gelation of chitosan with tripolyphosphate (TPP) through ionic cross-linking. A three-factor three-level central composite design (CCD) was introduced to perform the experiments. A quadratic polynomial model was generated to predict and evaluate the independent variables with respect to the dependent variables. Bay41-4109 was encapsulated in the chitosan nanoparticles were demonstrated by PLM, FTIR, DSC, XRD and TEM etc. The in vivo results suggest that Bay41-4109 nanoparticles have better bioavailability and would be a promising approach for oral delivery of Bay41-4109 for the treatment of HBV. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Mechanisms involved in breast cancer liver metastasis.
- Author
-
Rui Ma, Yili Feng, Shuang Lin, Jiang Chen, Hui Lin, Xiao Liang, Heming Zheng, and Xiujun Cai
- Subjects
- *
LIVER metastasis , *BREAST cancer patients , *CANCER cells , *DRUG development , *DRUG efficacy , *THERAPEUTICS - Abstract
Liver metastasis is a frequent occurrence in patients with breast cancer; however, the available treatments are limited and ineffective. While liver-specific homing of breast cancer cells is an important feature of metastasis, the formation of liver metastases is not random. Indeed, breast cancer cell factors contribute to the liver microenvironment. Major breakthroughs have been achieved recently in understanding breast cancer liver metastasis (BCLM). The process of liver metastasis consists of multiple steps and involves various factors from breast cancer cells and the liver microenvironment. A further understanding of the roles of breast cancer cells and the liver microenvironment is crucial to guide future work in clinical treatments. In this review we discuss the contribution of breast cancer cells and the liver microenvironment to liver metastasis, with the aim to improve therapeutic efficacy for patients with BCLM. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.